Keyphrases
Sickle Cell Disease
100%
Acute Pain Episodes
100%
Eptifibatide
100%
Placebo
37%
Point Estimate
37%
Median Time
25%
Crisis Resolution
25%
Bleeding Episodes
25%
No Significant Difference
12%
Synthetic Peptides
12%
Treatment Group
12%
Bleeding
12%
Double-blind Placebo-controlled Trial
12%
Thrombocytopenia
12%
Intent-to-treat Analysis
12%
Hospital Discharge
12%
Platelet Activation
12%
Peptide Inhibitor
12%
Major Bleeding
12%
Opioid Use
12%
SC-1
12%
Minor Bleeding
12%
Time to Discharge
12%
Medicine and Dentistry
Sickle-Cell Disease
100%
Pain
100%
Eptifibatide
100%
Placebo
50%
Arm
25%
Bleeding
25%
Group Therapy
12%
Receptor
12%
Synthetic Peptide
12%
Thrombocyte Activation
12%
Thrombocytopenia
12%
Opiate
12%
Intention-to-Treat Analysis
12%
Patient with Sickle Cell Disease
12%
Major Bleeding
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sickle Cell Anemia
100%
Pain
100%
Eptifibatide
100%
Placebo
50%
Bleeding
37%
Receptor
12%
Opiate
12%
Synthetic Peptide
12%
Thrombocytopenia
12%
Neuroscience
Eptifibatide
100%
Placebo
50%
Platelet
12%
Eicosanoid Receptor
12%
Intention
12%
Opiate
12%
Synthetic Peptide
12%
Biochemistry, Genetics and Molecular Biology
Eptifibatide
100%
Eicosanoid Receptor
12%
Thrombocyte Activation
12%
Thrombocytopenia
12%